Sanofi India Ltd

For the fifth consecutive session, Sanofi India Ltd has closed lower, slipping to a fresh 52-week low of Rs 3,056 on 22 Sep 2026. This decline extends the stock’s downward trajectory, which has now erased over 39% of its value in the past year, significantly underperforming the broader Sensex index.

Sanofi India Ltd has been downgraded from a Hold to a Sell rating by MarketsMOJO as of 21 Sep 2026, reflecting deteriorating technical indicators and subdued financial performance. Despite strong management efficiency and attractive valuation metrics, the stock’s bearish technical trend and poor long-term growth prospects have prompted a cautious stance from investors.

Sanofi India Ltd has experienced a notable shift in its technical momentum, with multiple indicators signalling a bearish trend. The stock’s recent downgrade from a Hold to a Sell rating reflects deteriorating price action and weakening market sentiment within the Pharmaceuticals & Biotechnology sector.

Sanofi India Ltd has experienced a subtle yet notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a marginal day change of -0.03%, the stock’s technical indicators reveal a complex interplay of bullish and bearish signals, reflecting cautious investor sentiment amid broader market pressures.

Sanofi India Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. Despite a modest downgrade in daily price action, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators. This analysis delves into the recent technical developments and their implications for investors navigating the Pharmaceuticals & Biotechnology sector.

Sanofi India Ltd has seen its investment rating upgraded from Sell to Hold as of 15 Sep 2026, reflecting a nuanced improvement in its technical outlook and valuation metrics despite ongoing challenges in financial growth and market performance. The upgrade is driven primarily by a shift in technical indicators, attractive valuation relative to peers, and strong management efficiency, though tempered by subdued sales growth and profit declines over recent years.

Sanofi India Ltd has experienced a subtle shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, reflecting a complex interplay of technical indicators. Despite a modest day gain of 1.64%, the stock remains under pressure over longer time frames, with mixed signals from MACD, RSI, and moving averages suggesting cautious investor sentiment in the Pharmaceuticals & Biotechnology sector.

Sanofi India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 September 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Sanofi India Ltd has been downgraded from a Hold to a Sell rating by MarketsMOJO as of 1 September 2026, reflecting deteriorating technical indicators and subdued financial performance. Despite strong management efficiency and a net-debt-free balance sheet, the company’s long-term growth outlook and recent price trends have raised concerns among analysts, prompting a reassessment of its investment appeal.

Sanofi India Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a modest daily price increase of 0.74%, the pharmaceutical company’s technical parameters suggest caution for investors amid weakening momentum and deteriorating moving averages.

Sanofi India Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 24 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Sanofi India Ltd has experienced a subtle shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, as reflected in a complex interplay of technical indicators. Despite a modest day gain of 1.14%, the stock remains under pressure with a MarketsMOJO Mojo Grade downgraded from Hold to Sell, signalling caution for investors amid mixed signals from MACD, RSI, and moving averages.

Sanofi India Ltd has seen its investment rating downgraded from Hold to Sell following a comprehensive reassessment of its quality, valuation, financial trends, and technical indicators. Despite some strengths such as high return on equity and net-debt free status, the company’s deteriorating financial performance and bearish technical signals have prompted a cautious stance from analysts.

Sanofi India Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s recent downgrade from a Hold to a Sell rating by MarketsMOJO reflects growing concerns over its price performance and technical outlook amid a challenging market environment.

Sanofi India Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 August 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Sanofi India Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.